Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof

Abstract

The invention provides a pharmaceutical composition for treating ulcerative colitis and a micro-pill preparation with colon-targeted properties thereof, relating to the technical field of medicines. The pharmaceutical composition takes bighead atractylodes rhizome as a monarch medicine, coptis as a ministerial medicine and radix sileris as an adjuvant medicine, and is prepared from the following components in concrete parts by weight: 30-60 parts of bighead atractylodes rhizome, 30-45 parts of coptis and 30-60 parts of radix sileris. The extracts of the bighead atractylodes rhizome, coptis and radix sileris are respectively prepared into stomach-soluble micro-pills and intestine-soluble micro-pills, and then, the stomach-soluble micro-pills and the intestine-soluble micro-pills are proportionally mixed to prepare an oral colon-targeted administration system of micro-pills prepared from bighead atractylodes rhizome and coptis, thereby realizing the purpose of colon-targeted administration and better exerting the effect of the composition. The pharmaceutical composition provided by the invention and the oral colon-targeted administration system of micro-pills prepared from bighead atractylodes rhizome and coptis have the dual-treatment characteristics of treating both principal and secondary aspects of diseases and simultaneously considering overall and local aspects, and are safe and convenient in oral administration and low is cost. The animal experiment shows that the pharmaceutical composition and the oral colon-targeted administration system have an obvious treatment effect on ulcerative colitis (the treatment effect is close to or even superior to the treatment effect of a positive control medicine salicylazosulfapyridine (SASP)), and have small side effects, thus the pharmaceutical composition and the oral colon-targeted administration system can be used for preparing medicines for treating ulcerative colitis.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a traditional Chinese medicine composition for treating ulcerative colitis and a pellet preparation with colon-targeting properties. Background technique [0002] Ulcerative colitis (Ulcerative Colitis, UC), also known as chronic nonspecific ulcerative colitis, is a common autoimmune disease. The main clinical symptoms are recurrent diarrhea, mucus pus and blood, abdominal pain or tenesmus. The course of the disease is protracted and difficult to heal. It lasts for several months to decades. 80% of the patients will have recurrent attacks and the condition will continue to worsen. Patients with a course of 30 years The rate of canceration can be as high as 40%, so it is defined as one of 14 refractory diseases by the World Health Organization (WHO). Ulcerative colitis can occur at any age, but it is more common in 20-40 years old. The incidence rate in my country is about 5-40 / 10...

AI Technical Summary

Problems solved by technology

After oral administration of ordinary tablets and capsules, the drug has been absorbed or degraded by the whole body before reaching the colon; after rectal administration of traditional Chinese medicine external treatment preparations such as suppositories and enemas, the drug is limited to the rectum and descending colon, and cannot reach the transverse colon, ascending colon, etc. Major ulcer lesions such as the colon affect the efficacy of the drug

Images